Mixed connective tissue disease (MCTD) is a complex and relatively rare autoimmune disorder. It shares symptoms with lupus, systemic sclerosis, and myositis.

MCTD is a challenging condition that can profoundly affect an individual’s quality of life. The disease has an unpredictable course, involving a broad spectrum of symptoms from physical discomfort to potential emotional distress.

One of the primary challenges of MCTD is its diagnosis, which often involves a long process of physical evaluations, laboratory tests, and clinical assessments.

This article explores MCTD, including its symptoms, diagnosis, and treatment options.

A scientists putting a test tube in a rack in a laboratory.Share on Pinterest
Longhua Liao/Getty Images

MCTD is a complex autoimmune disorder in the spectrum of connective tissue diseases. It involves a combination of signs and symptoms overlapping at least two other connective tissue disorders, including:

MCTD’s hallmark is the presence of a specific autoantibody, known as anti-U1 ribonucleoprotein (RNP), which plays a pivotal role in the diagnosis.

This condition involves a wide range of symptoms that can affect various organs and systems within the body, making it challenging to understand and manage.

The symptoms of MCTD are diverse and can vary from person to person. Common symptoms include:

  • an extreme sensitivity to cold, leading to color changes in the fingers and toes, which doctors call Raynaud’s phenomenon
  • joint pain and swelling resembling RA
  • muscle weakness and inflammation
  • skin symptoms, such as skin tightening or rashes
  • swollen hands and fingers
  • fatigue and malaise
  • difficulty swallowing
  • heart and lung issues
  • kidney issues

MCTD originates from an autoimmune response where the immune system mistakenly targets the body’s healthy tissues. In MCTD, the immune system specifically targets RNP molecules.

Typically, RNP molecules reside within the cell nucleus, shielded from immune detection. However, they can become exposed to the immune system during cell death or decay.

Because RNP is similar to disease-causing single-celled organisms, such as viruses, the body can mistake RNP in the body as a potential threat and try to attack it.

Scientists do not fully understand why some people get MCTD while others do not. Some factors that may play a role include:

  • genes that influence the immune system
  • genes that influence the body’s ability to destroy or hide cell debris
  • exposure to substances similar to RNP, such as viruses

Of those who get MCTD, 75% are female. It is unclear why this is, but females are generally more likely to develop autoimmune disorders than males. Researchers are still learning why this is.

Diagnosing MCTD is often challenging due to its overlapping symptoms with other connective tissue diseases as well as lupus. A thorough evaluation by a rheumatologist is often necessary.

Doctors rely on a combination of clinical criteria, blood and antibody testing, and imaging studies to make an accurate diagnosis.

In MCTD, people often have low levels of red blood cells, or anemia, and low levels of white blood cells, known as leukopenia. Other substances in the blood may be high, such as:

  • a type of protein called gamma globulin
  • certain antibodies, including anti-U1-RNP and anti-U1 70kd
  • rheumatoid factor
  • anti-cyclic citrullinated peptide antibodies
  • muscle enzymes

If a person has lung or heart issues, chest X-rays may help doctors identify fluid around the lungs or an enlarged heart. Joint X-rays can reveal joint changes, such as erosion.

They may also order echocardiograms and electrocardiograms to assess heart health or to look for signs of pulmonary hypertension. These tests help doctors understand the extent of the disease and guide treatment decisions.

The treatment of MCTD aims to manage symptoms, reduce inflammation, and suppress the immune system’s atypical response. This typically involves medications such as:

  • Nonsteroidal anti-inflammatory drugs (NSAIDs): NSAIDs can help manage pain, reduce inflammation, and relieve symptoms such as joint pain and swelling.
  • Corticosteroids: These powerful anti-inflammatory drugs can help to suppress the immune system. They effectively reduce inflammation and manage symptoms, but long-term use can have side effects.
  • Disease-modifying antirheumatic drugs (DMARDs): Thesemedications slow the progression of MCTD and prevent joint damage. Examples of DMARDs include methotrexate, hydroxychloroquine, and azathioprine. Some suppress the immune system, but hydroxychloroquine does not.
  • Immunosuppressive agents: In more severe cases, medications that further suppress the immune system may be necessary to reduce inflammation and prevent organ damage. Examples include cyclophosphamide and mycophenolate mofetil.
  • Biologic therapies: These newer medications, such as rituximab, target specific immune system components and can effectively manage MCTD symptoms.

Some individuals need continuous treatment with medications, while others may only need to take them during flare-ups.

Food and diet for MCTD

A balanced and nutritious diet is essential for overall health and can help support the immune system and potentially ease MCTD symptoms. A person can aim to consume:

  • fruits and vegetables
  • whole grains
  • lean proteins
  • healthy fats, such as olive oil

Doctors may also recommend avoiding saturated fat, added sugars, and excessive salt to help reduce inflammation. Vitamin D also plays a role in regulating the immune system and maintaining healthy bones. People can get vitamin D through safe sunlight exposure or from food.

A person needs to speak with a doctor for testing to detect any nutritional deficiencies. If it is not possible to get enough nutrients from food, it may be beneficial to try supplements. Individuals always need to discuss this with a doctor first, as some supplements could interact with medications. Doctors can also advise on the correct dosage to take.

The prognosis for individuals with MCTD varies widely depending on the severity of their symptoms and the response to treatment.

Nearly 1 in 3 people with MCTD experience a complete resolution of their symptoms. However, another 1 in 3 develop life threatening complications. The outlook depends on the organs the disease has affected, the degree of inflammation, and the rate of disease progression.

With appropriate medical care and management, many people with MCTD can lead fulfilling lives. However, monitoring the disease and promptly addressing complications is essential.

Mixed connective tissue disease (MCTD) is a complex autoimmune disorder with symptoms similar to those of other connective tissue diseases and some other autoimmune disorders. It can cause a range of symptoms, such as joint pain, swelling, skin symptoms, fatigue, and malaise.

While its exact cause remains elusive, early diagnosis and appropriate treatment of MCTD can help reduce the symptoms in many cases. With support, many individuals with MCTD can lead fulfilling lives while managing the condition.